Evox Therapeutics raises £35.5m series-B

New investors in the round included GV (formerly Google Ventures), Cowen Healthcare Investments, Panacea Healthcare Venture, Borealis Ventures and a small number of private investors.

Existing investors Oxford Sciences Innovation and Oxford University also participated in the round. Evox has previously received £10m in seed financing.

The firm said the round would fund its exosome-based therapeutics pipeline, including progression of several proprietary rare disease assets and continued development of its exosome drug platform.

Company
Founded in 2016 and based in Oxford, Evox undertakes engineering of exosomes – nano-sized vesicles that are secreted by all cells and are found in all biological fluids – to enable a wide variety of drugs to reach previously inaccessible tissues and compartments. These include crossing the blood-brain barrier to deliver drugs to the central nervous system, intracellular delivery of biologics and extra-hepatic delivery of RNA therapeutics.

People
Evox Therapeutics – Antonin de Fougerolles (CEO).
Redmile Group – Jeremy Green (founder).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• UK / Ireland
• Healthcare
• United Kingdom
• Venture